Literature DB >> 14532742

[A clinical and immunohistochemical study on gastrointestinal stromal tumor].

Eun Jung Lee1, Ok Jae Lee, Tae Hyo Kim, Woon Tae Jung.   

Abstract

BACKGROUND/AIMS: As the relationship between gastrointestinal stromal tumors (GIST) and interstitial cells of Cajal had become clear, GIST is defined as CD117 positive mesenchymal tumors, and recognized as a new distinct entity among mesenchymal tumors presenting as gastrointestinal submucosal tumors (SMT). To evaluate GISTs in the category of SMTs, we analyzed mesenchymal SMTs immunohistochemically and clinicopathologically.
METHODS: Forty-five patients with mesenchymal SMTs, who received surgical or endoscopic resection were retrospectively analyzed for clinical parameters. Immunohistochemical staining for CD117, CD34, NSE, SMA, and S-100 was also performed.
RESULTS: Among 45 tumors, 41 (91.1%) expressed CD117 and were diagnosed as GIST. The most frequent location was the gastric body. Except esophageal location (73.3%), GISTs accounted for 100% of SMTs in the gastrointestinal tract. The mixed myoid-neural differentiated type and the spindle cell shape were most common. Metastasis was observed in 5 patients (11%). All of them had tumors larger than 5 cm and died. Their mean survival was 4.6 months.
CONCLUSIONS: GIST accounted for majority (91.1%) of SMTs. The presence of metastasis and tumor size at the time of diagnosis indicate poor prognostic factors. Immunohistochemical study is necessary for exact diagnosis of GIST.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14532742

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  1 in total

1.  Gastrointestinal stromal tumors in Koreans: it's incidence and the clinical, pathologic and immunohistochemical findings.

Authors:  Kyoung-Mee Kim; Dong Wook Kang; Woo Sung Moon; Jae Bok Park; Cheol Keun Park; Jin Hee Sohn; Jin Sook Jeong; Mee-Yon Cho; So-Young Jin; Jong Sang Choi; Dae Young Kang
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.